The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences.

J&J's vet Ross has left for Henry Shein, House E&C Committee staff director Andres takes public affairs job at BIO, and Infinity's Kutok has…

Stanford University scientists converted pancreatic alpha cells to insulin-producing beta cells in mice by blocking the production of a pair of proteins.

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…